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Abstract
In chronic neurodegenerative diseases associated with aggregates of misfolded proteins (such as Alzheimer’s, Parkinson’s
and prion disease), there is an early degeneration of presynaptic terminals prior to the loss of the neuronal somata.
Identifying the mechanisms that govern synapse degeneration is of paramount importance, as cognitive decline is strongly
correlated with loss of presynaptic terminals in these disorders. However, very little is known about the processes that link
the presence of a misfolded protein to the degeneration of synapses. It has been suggested that the process follows
a simple linear sequence in which terminals that become dysfunctional are targeted for death, but there is also evidence
that high levels of activity can speed up degeneration. To dissect the role of activity in synapse degeneration, we infused
the synaptic blocker botulinum neurotoxin A (BoNT/A) into the hippocampus of mice with prion disease and assessed
synapse loss at the electron microscopy level. We found that injection of BoNT/A in naı¨ve mice caused a significant
enlargement of excitatory presynaptic terminals in the hippocampus, indicating transmission impairment. Long-lasting
blockade of activity by BoNT/A caused only minimal synaptic pathology and no significant activation of microglia. In mice
with prion disease infused with BoNT/A, rates of synaptic degeneration were indistinguishable from those observed in
control diseased mice. We conclude that silencing synaptic activity neither prevents nor enhances the degree of synapse
degeneration in prion disease. These results challenge the idea that dysfunction of synaptic terminals dictates their
elimination during prion-induced neurodegeneration.
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Introduction
Since the first suggestion that synaptic loss is associated with the
degree of cognitive decline in Alzheimer’s disease (AD) [1] there
has been a growing body of evidence to show that synapse loss is
an early component of the neuropathology of chronic neurode-
generative diseases associated with the accumulation of misfolded
proteins such as AD, Parkinson’s disease, Huntington’s disease and
prion disease. In some animal models that mimic aspects of the
amyloid accumulation in AD there is loss of synapses but not in all
models [2,3]. In humans with amyotrophic lateral sclerosis (ALS)
and animal models of the disease there is loss of neuromuscular
junction synapses prior to the degeneration of the neuronal cell
body [4,5]. In laboratory models of prion disease there is well
documented degeneration of synapses from the hippocampus prior
to the degeneration of neuronal cell bodies [6,7]. Despite the
obvious importance of synapse degeneration in these diseases we
know remarkably little about the underlying cellular and
molecular events by which a misfolded protein or peptide leads
to synapse degeneration.
In the ME7 model of prion disease, a tractable laboratory model
of chronic neurodegeneration, synapse degeneration in the
stratum radiatum of the hippocampus is characterised by the
degeneration of the pre-synaptic compartment prior to the loss or
degeneration of the post-synaptic dendritic spine. Biochemical
analysis has shown there is a loss of synaptic vesicle proteins,
cysteine string protein (CSP), VAMP-2, and synapsin, that
precedes the reduction of proteins in the post-synaptic compart-
ment [8]. Electron microscopy studies also reveal degeneration of
the pre-synaptic compartment prior to the post-synaptic dendritic
spine [6,7]. These changes are readily quantified as the
degenerating presynaptic terminals appear electron dense, there
is loss of vesicle integrity and the post-synaptic density (PSD)
becomes progressively curved as it envelops the degenerating pre-
synaptic terminal [7].
The early loss of synaptic vesicle protein CSP is of particular
interest since it has been shown that mice lacking this protein are
susceptible to a synaptic degeneration phenotype [9]. Further-
more, it is the most active neurons with a high firing rate,
GABAergic neurons, in which the synaptic loss is most apparent
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[10]. There is also evidence that neuronal activity may play a role
in the formation of toxic protein aggregates as in cellular models of
spinocerebellar ataxia type 3 [11], in the release of amyloid-ß (Aß)
peptides [12,13] and in Aß mediated spine loss in hippocampal
slices [14]. Studies on the SOD1 mouse a model of familial
amyotrophic lateral sclerosis (ALS) show that it is the fast-
fatigueable neuronal population, those with the highest firing rate,
that are the first to degenerate [15]. These data suggest that
neuronal activity is involved in degeneration in protein misfolding
diseases and synapses with high rates of exo/endocytosis may be
particularly vulnerable to disease-induced death. On the other
hand, as discussed above, it is evident that disruption of synaptic
function (‘‘synaptopathies’’) represents a major early component of
neurodegenerative conditions. In this scenario, synapses with
reduced or impaired activity may be selectively targeted for
degeneration and removed from the neuronal network during the
early stages of the disease. If this view were correct, pharmaco-
logical impairment of synaptic transmission should speed up and
aggravate synapse degeneration. Altogether, the role of activity in
synapse degeneration in diseases associated with accumulation of
misfolded protein remains undefined.
In order to understand whether synaptic activity is an important
determinant of synapse degeneration we have investigated
whether prolonged blockade of synaptic activity impacts on
synapse degeneration in prion disease. In previous studies we
have shown that the injection of botulinum toxin serotypes A and
E (BoNT/A and BoNT/E) into the rodent hippocampus produces
a sustained blockade of synaptic transmission via cleavage of the
synaptic protein SNAP-25 (synaptosomal-associated protein of 25
kDa). While the effects of BoNT/E are relatively short-lasting
(about two weeks, [16,17,18]), the action of BoNT/A is much
more persistent and lasts for several months [17,19]. Due to its
long-lasting effects, BoNT/A is widely used in the clinical setting
for the treatment of pathologies characterized by hyper-excitability
of peripheral nerve terminals [20,21,22,23,24]. We thus injected
BoNT/A into the hippocampus of animals at the early stages of
the well-defined model of ME7 prion disease and studied how the




All procedures were performed according to the guidelines of
the Italian Ministry of Health for care and maintenance of
laboratory animals (law 116/92), and in strict compliance with the
European Communities Council Directive n. 86/609/EEC.
Animal experimentation at the CNR Neuroscience Institute was
approved by the Italian Ministry of Health (authorization # 129/
20002A). Specifically, the experiments described in this study
were authorized by the Italian Ministry of Health via decree #
185/2009-B, released on November 4, 2009. All surgical
procedures were performed under deep anesthesia and all efforts
were made to ameliorate suffering of animals.
Animals and surgery
C57BL/6N mice were bred and group housed in the animal
facility of the CNR Neuroscience Institute in Pisa (Italy). When the
mice were 11 to 12 weeks old surgery was performed as previously
described [25]. Mice were anesthetized by intraperitoneal in-
jection of Avertin (2,2,2-tribromoethanol solution) (20 ml/kg) and
mounted in a stereotaxic frame (David Kopf Instruments,
Tujunga, CA). In 8 mice, 1 ml injections of a ME7 prion agent-
infected brain (ME7-animals) were made bilaterally into the dorsal
hippocampus with a 10-ml Hamilton syringe. The suspension was
slowly infused and the needle was left in place for 2 minutes before
being slowly withdrawn. Mice were placed in a heated recovery
chamber and when fully recovered re-housed in groups and
checked daily. At 4 weeks after the initiation of disease, 4 mice
were injected into the left hippocampus with BoNT/A (0.2 ml of
a 1 nM solution) as described below; 4 additional animals received
injection of vehicle solution (2% rat serum albumin in PBS). Mice
with ME7 prion disease plus vehicle (ME7+vehicle) or with
BoNT/A injection (ME7+BoNT/A animals) were killed at
12 weeks after disease initiation and tissues prepared for electron
microscopy as described below.
Botulinum neurotoxin injections
In C57BL/6N mice a stereotaxically guided injection of BoNT/
A (0.2 ml of a 1 nM solution) or vehicle (2% rat serum albumin in
PBS) was made into the dorsal hippocampus using fine glass
micropipettes as previously described [16,17]. Animals were killed
at 2, 4 and 8 weeks after BoNT/A injections and perfused for
electron microscopy as described below. Three animals per group
(vehicle and BoNT/A) were taken at each time point. A further
group of 8 animals were injected in the hippocampus with BoNT/
A (n= 4) or vehicle (n = 4) and killed at 8 weeks. Under deep
anesthesia, animals were perfused through the heart with freshly
prepared 4% paraformaldehyde and the brains processed for
immunocytochemistry (see below). In all BoNT/A injected
animals, including those previously injected with ME7, recovery
was uneventful and no overt behavioural abnormalities were
observed.
Electron microscopy
For electron microscopy mice were perfused with fixative
containing 3.4% paraformaldehyde, 1.25% glutaraldehyde, 0.2%
picric acid in 0.1 M phosphate buffer (final pH 7.2 to 7.4)
immediately after a short perfusion with heparinized saline. Tissue
blocks were cut on a vibratome and the area of CA1 pyramidal
layer and stratum radiatum was dissected out. Some adjacent
vibratome sections through the dorsal hippocampus were collected
in PBS and treated with a reducing agent (0.1 M boric acid,
pH 8.5) for 10 min before being processed for flee-floating
immunostaining for BoNT/A-truncated SNAP-25.
Microdissected areas were postfixed in 1% osmium tetroxide,
dehydrated and embedded in TAAB resin as previously described
[7]. Semithin (0.5 to 1 mm) sections were stained (1% v/v toluidine
blue in 1% w/v borax) and used to guide further cutting of the
specimen block into ultra-thin sections (60 to 70 nm). Ultra-thin
sections were picked up onto thin bar mesh copper palladium grids
and stained in Reynolds lead stain for 5 minutes. Grids were
examined using a Hitachi H7000 transmission electron micro-
scope with a MegaView III digital camera (Soft Imaging System)
and subsequently processed using Adobe Photoshop software
(Adobe Systems Incorporated, San Jose, CA).
Immunocytochemistry
Tissue blocks from mice eight weeks after BoNT/A injection
(n= 4) and their vehicle controls (n = 4) were sectioned at 40 mm
on a freezing microtome (Leica). Sections were through the dorsal
hippocampus at approximately 2 mm posterior to bregma,
comparable to the region studied by electron microscopy. Sections
were stained with an antibody that specifically recognizes the
BoNT/A-truncated form of SNAP-25 [17,26,27]. Briefly, sections
were sections were blocked with 10% normal horse serum in PBS
containing 0.25% Triton X-100 and then incubated overnight at
room temperature with the anti-cleaved SNAP-25 antibody (1:500
Neural Activity and Synapse Degeneration
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dilution; a kind gift of Dr. Rossetto, University of Padua). On the
following day, sections were incubated with Rhodamine Red X-
conjugated secondary antibody (1:400; Jackson ImmunoResearch)
for 2 h at room temperature. For Iba-1 immunostaining, sections
were blocked in 10% BSA, 0.3% Triton X-100 in PBS for 1.5 hr
at room temperature, then incubated with 1:500 anti-Iba-1 rabbit
polyclonal antibody (Wako, Japan), 1% BSA, 0.1% Triton X-100
in PBS, overnight at room temperature. The signal was revealed
by incubation in 1:400 anti-rabbit secondary antibody conjugated
to Rhodamine Red-X (Jackson ImmunoResearch, USA), 1%
BSA, 0.1% Triton X-100 in PBS, for 2.5 hr at room temperature.
Sections were mounted on glass slides using VectaShield mounting
medium (Vector Laboratories, USA). Images of cleaved SNAP-25
and Iba-1 immunoreactivity in the hippocampus were acquired
with a confocal laser scanning microscope (Leica Microsystems,
Germany).
Quantitative analysis
Electron microscopy images were taken from the stratum
radiatum at a magnification of x20,000 or x40,000. The images
were sampled in a quasi-random fashion as previously described
[7] but avoiding blood vessels, the major dendrites and rare cell
somas within the stratum radiatum. Measurements of the PSD and
pre-synaptic terminal areas were performed on asymmetric
synapses at 2, 4 and 8 weeks after injection with BoNT/A (or
vehicle) on images taken at x20,000 magnification. The area of
a PSD was measured only if synaptic vesicles were present in the
same section and typical membrane apposition between pre-
synaptic and post-synaptic element was present. A total of 115–
636 PSDs and pre-synaptic terminals were measured for each time
point from three to six different sections at least ten sections apart
for both BoNT/A and vehicle injected animals. The areas of pre-
synaptic terminals containing synaptic vesicles and PSDs were
included only if synaptic terminal profiles were clearly visible. In
a subset of the fields taken at x40,000 the size (equivalent
diameter), circularity and density of synaptic vesicles was measured
in asymmetric synapses from BoNT/A-treated and control
animals at 4 weeks after injection. Density of vesicles was
measured in 30 synaptic terminals per group from 3 vehicle-
and 3 BoNT/A-injected mice. Circularity and vesicle diameter
were determined from 1962 and 927 synaptic vesicles from
BoNT/A- and vehicle-treated terminals. Measurement of PSD
areas, presynaptic terminal areas, vesicle area and circularity were
performed using ImageJ software (U.S. National Institutes of
Health, http://rsb.info.nih.gov/ij/download.html). The identities
of images were coded and only revealed to the observer after the
data analysis was complete.
To examine synaptic degeneration, images from prion animals
were taken from the stratum radiatum at a magnification of
x20,000. The analysis was conducted in ME7-only animals (10,
12, 16 and 18 weeks after injection; n= 3 per time point) and ME7
mice treated with vehicle (ME7+vehicle; n = 4) or BoNT/A
(ME7+BoNT/A; n= 4). For each image (52–136 images per
condition) we determined the number of degenerating and healthy
synapses. We scored as degenerating terminals those boutons with
a typical dark appearance and a curved PSD [7]. Results were
expressed either as the percentage of degenerating/healthy
synapses in each condition or as the mean number of degenerat-
ing/healthy synapses per image.
The density of Iba-1-positive cells was quantified by means of
the Stereo Investigator software (MicroBrightField, USA), using
three-dimensional counting boxes (100 mm6100 mm630 mm)
positioned in the stratum radiatum of the CA1 region. For each
animal, at least five sections were examined with the operator
blind to experimental treatment.
Statistics
Statistical analysis was performed with SigmaPlot (version 11).
Differences between two groups were assessed with Student’s t-test
for data normally distributed, and with Mann-Whitney rank sum
test for data non-normally distributed. Differences between four
groups were evaluated with one way analysis of variance
(ANOVA) followed by Holm-Sidak test or Dunn’s test. Normality
of distributions was assessed with a Kolmogorov-Smirnov test.
Results
Effect of BoNT/A on synaptic morphology in naı¨ve mice
The long-term effects of BoNT/A on synapses of the CNS
following direct injection into the brain parenchyma have not been
previously studied, although there have been reports on the impact
of BoNT/A and tetanus neurotoxin on neurons of the peripheral
nervous system [28,29]. We addressed this issue by injecting adult
mice into the left hippocampus with BoNT/A (1 nM solution,
0.2 ml; n = 13 animals) or vehicle solution (0.2 ml of 2% rat serum
albumin in PBS; n= 13). Animals were killed 2, 4 and 8 weeks
after injection and the CA1 stratum radiatum of the treated side
was processed for electron microscopy analysis.
The most striking feature of the BoNT/A-treated tissue was the
presence of enlarged asymmetric pre-synaptic terminals, which
were particularly conspicuous at 4 weeks post-injection (Figure 1).
No ultrastructural changes were evident in symmetric, presumably
GABA-ergic synapses. Apart from the enlarged pre-synaptic
compartment, with an apparent increase in the number of
vesicles, the pre-synaptic element appeared normal with no
increase in lysosomes or other organelles: similarly the post-
synaptic densities (PSD) and dendritic spines appeared morpho-
logically normal (Figure 1). We measured the area of the pre- and
post-synaptic elements in BoNT/A- and vehicle-injected hippo-
campi. As shown in Figure 2A the area of the pre-synaptic
compartment is larger in BoNT/A animals than controls at all
time points (Kruskal-Wallis One Way Analysis of Variance on
Ranks, p,0.001; post hoc Dunn’s test, p,0.05) with the
maximum change present at 4 weeks post injection, where there
is a more that two-fold increase relative to controls (p,0.001). The
pre-synaptic elements at the 8 week timepoint are then reduced
relative to size at 4 weeks and closer to the size seen in vehicle-
treated animals (Figure 1A and Figure 2A). In contrast to the pre-
synaptic elements the area of PSD is not significantly different
from controls at any timepoint examined (Kruskal-Wallis One
Way Analysis of Variance on Ranks, p.0.05) (Figure 2B).
Since the pre-synaptic compartment was significantly enlarged
we were interested to learn whether there was an increase in the
density of the vesicles and if so whether this might reflect the
transport of immature vesicles into the pre-synaptic compartment.
In the pre-synaptic terminals seen at 4 weeks post injection there is
an increase in the density of vesicles (Figure 2C; Student’s t-test,
p,0.05) consistent with the observation that the area of these
synapses is overtly larger and populated with a larger number of
vesicles. However, the vesicles of these enlarged synapses are very
similar in both size and circularity to the vesicles of naı¨ve synapses
(Figure 2D, E; circularity index, t-test, p.0.05). There is a small
but significant difference in the size of BoNT/A and control
synaptic vesicles (Mann-Whitney Rank Sum test, p,0.05) but
there was no evidence of a population of immature vesicles with
a more heterogeneous size profile such as we might expect if
a population of immature vesicles were being transported from the
Neural Activity and Synapse Degeneration
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cell body or formed locally [30]. We did not observe any increase
in dense core vesicles, also associated with synapse development, in
the BoNT/A treated animals (data not shown).
There was no evidence of neuronal/synaptic degeneration in
the EM sections analyzed 2 or 8 weeks after BoNT/A injection.
However, in the animals sacrificed at 4 weeks, we detected a subset
of dark, electron-dense synapses with ‘‘curved’’ PSDs, that
resemble degenerating terminals seen in early stages of prion
disease (Fig. 3A). These degenerating terminals represented 6.6%
of the total synaptic pool at 4 weeks (Fig. 3B). Since no dark
profiles were observed either 2 or 8 weeks after BoNT/A, we
interpret this finding as a transient wave of synaptic degeneration
caused by activity blockade in a small subset of hippocampal
terminals.
A sensitive indicator of any pathology in the brain are changes
in the morphology and number of microglia [31,32]. To
determine whether there is ongoing synaptic pathology after
long-term activity blockade and an associated microglia response,
we stained sections from BoNT/A and vehicle animals with Iba-1
to reveal the microglia population 8 weeks after treatment
(Figure 4A, B). The microglia in the hippocampus of BoNT/A
and naı¨ve animals were similar in morphology. There was
a tendency for increased microglial cell density in BoNT/A mice,
but this trend was not significant (Figure 4C; t-test, p = 0.12),
consistent with the lack of signs of pathology in the electron
microscopy sections at 8 weeks. Staining for CD68, a marker of
activated microglia, also revealed no significant differences
between vehicle and BoNT/A animals at 8 weeks (data not
shown). Furthermore, in the electron microscopy there was no
evidence of synaptic envelopment or interposition of processes
between the pre-and post-synaptic specializations that might be
indicative of a microglia response to the silent synapses. Adjacent
sections were stained for BoNT/A-truncated SNAP-25 to
demonstrate that at 8 weeks post-injection the effect of the toxin
was still present (Figure 4D, E). The presence of cleaved SNAP-25
was widespread throughout the dorsal hippocampus, with strong
staining in the stratum radiatum (Figure 4D, E) although it should
be noted that this does not distinguish between the persistence of
the toxin, the delayed turnover of the cleaved fragment or possibly
both [17,27].
Effect of BoNT/A on synaptic degeneration in prion
disease
The features of degeneration of asymmetric synapses in the
hippocampus during the progression of ME7 induced prion
disease have been previously described [6,7]. The synaptic vesicles
in the pre-synaptic terminal lose their definition and ultrastructural
integrity, the pre-synaptic compartment is electron dense, and
strikingly the PSD is closely apposed to and appears progressively
curved around the degenerating pre-synaptic terminal. The darker
and more degenerate the pre-synaptic terminal the more curved
the PSD appears [7].
Here, we first determined the time-course of synaptic loss by
scoring healthy and degenerating boutons in the CA1 stratum
radiatum at different times after intrahippocampal delivery of the
Figure 1. Ultrastructure of BoNT/A-treated hippocampal syn-
apses. Representative electron micrographs of CA1 stratum radiatum
in animals treated with vehicle (VEH) and at different times (2, 4 and
8 weeks) after BoNT/A infusion. There was no significant difference
between the control groups at 2, 4 and 8 weeks after vehicle injection
and the data from these groups has been merged. High magnification
pictures are shown in the insets. Note enlarged presynaptic terminals
following BoNT/A. Scale bar = 500 nm (250 nm for insets).
doi:10.1371/journal.pone.0041182.g001
Neural Activity and Synapse Degeneration
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e41182
Figure 2. Quantification of the ultrastructural changes in BoNT/A-treated synapses. (A, B) Areas of presynaptic terminals (A) and PSDs (B)
in mice infused with vehicle (VEH) or BoNT/A. BoNT/A treatment increases the surface area of presynaptic boutons at all time points examined (2,4
and 8 weeks; one way ANOVA on ranks followed by Dunn’s test, p,0.05). PSD areas are unaffected (one way ANOVA on ranks, p.0.05). Data for each
group are summarized by a box chart, in which the horizontal lines denote the 25th, 50th, and 75th percentile values, and the error bars denote the
5th and 95th percentile values. Numbers of synapses analyzed are as follows: VEH, n = 636; BoNT/A 2 weeks, n = 505; BoNT/A 4 weeks, n = 185; BoNT/
A 8 weeks, n = 195. (C) Density of synaptic vesicles is significantly increased in BoNT/A animals at 4 weeks as compared to vehicle controls (VEH;
Student’s t-test, p,0.05). Data are mean 6 SE. (D) Synaptic vesicle diameter is slightly larger 4 weeks after BoNT/A (Mann-Whitney rank sum test,
p,0.05). (E) Circularity of vesicles is identical in vehicle- and BoNT/A-treated terminals (t-test, p.0.05). The SE is too small to be visible. ***, p,0.001;
*, p,0.05. Density, diameter and circularity were measured in n = 1959 and n=926 vesicles, respectively, from BoNT/A and vehicle terminals at
4 weeks.
doi:10.1371/journal.pone.0041182.g002
Figure 3. Neuropathological changes in a subset of BoNT/A-treated terminals at 4 weeks. (A) Representative electron micrograph
showing a degenerating, dark synaptic terminal with curved PSD. Scale bar = 250 nm. (B) Percentage of degenerating synapses in vehicle (VEH)- and
BoNT/A-treated animals. Dark terminals with a curved PSD (,120 deg) were scored as degenerating synapses. *, p,0.05. A total of 100 terminals
were scored for each of three vehicle- and BoNT/A-injected animals at 4 weeks.
doi:10.1371/journal.pone.0041182.g003
Neural Activity and Synapse Degeneration
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ME7 prion agent. Sections were taken from ME7 mice of
a previous study [7]. We found that on average about 30% of the
boutons were degenerating at 10 weeks. As the disease progresses,
the ratio of degenerating synapses increased to reach a maximum
16–18 weeks after ME7 (Fig. 5A). In parallel, the proportion of
healthy terminals decreased steadily from 10 to 18 weeks (Fig. 5A).
On the basis of these findings, we selected the 12 weeks time-point
for the analysis of the effects of synaptic blockade on synapse
degeneration. Indeed, this time-point corresponds to an in-
termediate phase of the degeneration process that allows us to
measure BoNT/A-mediated decreases or increases in the degree
of synaptic loss.
We have previously shown that immediately after the injection
of ME7-infected or normal brain homogenate into the mouse
hippocampus there is an acute inflammatory response to the
delivery of a high concentration of protein but this resolves by
4 weeks [33]. We thus injected ME7-animals with BoNT/A (n= 4)
or vehicle (n = 4) into the dorsal hippocampus at 4 weeks after the
initiation of the disease. All animals were killed 12 weeks after
ME7. Since the BoNT/A serotype has very long lasting effects
[17,27] we reasoned that silencing synaptic activity for many
weeks prior to the onset of significant synaptic degeneration rather
than acutely would provide the most likely scenario for an impact
on synapse survival.
We found that at 12 weeks after the initiation of disease the
ratio of degenerating to intact synapses was the same (Student’s t-
test, p = 0.67) in both the ME7 animals from Siskova et al. (2009)
and the ME7+vehicle animals used in this study (Fig. 5A, B). In
ME7+BoNT/A animals it was apparent that there were asym-
metric synapses undergoing degeneration with the same features as
those seen in ME7+vehicle animals, with loss of vesicle integrity,
electron dense pre-synaptic compartment and curvature of the
PSD around the degenerating pre-synaptic component (Fig. 6).
The post-synaptic dendritic spine showed no signs of degeneration
(Fig. 6). Quantification of the ratio of degenerating synapses to
total synapses revealed no significant differences between ME7+-
vehicle animals (33.765.4%) and ME7+BoNT/A mice
(33.8611.5%; Student’s t-test, p = 0.97; Fig. 5B). We also analyzed
Figure 4. Lack of significant microglial activation 8 weeks after BoNT/A. (A, B) Representative immunostaining for the microglial marker Iba-
1 in the CA1 stratum radiatum of mice treated with vehicle (A, VEH) and BoNT/A (B). Scale bar = 100 mm. (C) Cell countings reveal no significant
differences in microglial density between vehicle and BoNT/A-infused animals (t-test, p.0.05). (D, E) Immunostaining for cleaved SNAP-25 (red)
demonstrates strong labeling in the CA1 stratum radiatum of BoNT/A-treated animals (E). No labeling is evident in vehicle mice (D). Green, Yoyo-1
nuclear counterstaining. Pyr, stratum pyramidale; s.r., stratum radiatum. Scale bar = 100 mm.
doi:10.1371/journal.pone.0041182.g004
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the absolute density of intact/degenerating synapses per image
and again we found that the values of ME7+vehicle and
ME7+BoNT/A mice were perfectly superimposable (Student’s t-
test, p = 0.54 for healthy synapses and p=0.19 for degenerating
boutons; Fig. 5C). To control whether BoNT/A was effective in
prion-injected hippocampi, a subset of vibratome sections adjacent
to those used for electron microscopy were stained for BoNT/A-
truncated SNAP-25 and showed the expected labeling in the
stratum radiatum (data not shown). These data demonstrate that
BoNT/A-mediated silencing of synaptic activity has no effect on
synaptic degeneration.
Discussion
In this study we have investigated how synaptic activity
influences synapse degeneration in mouse prion disease. We
hypothesized that silencing synaptic activity would delay or
prevent the onset of synapse degeneration since there is evidence
to suggest that higher levels of neuronal activity are associated with
synapse and neuronal degeneration [10,15]. To interfere with
synaptic activity we employed the clostridial neurotoxin BoNT/A,
a bacterial enzyme that causes a persistent and highly selective
effect on transmitter release via cleavage of the SNARE protein
SNAP-25 [17,27,34]. BoNT/A treatment in naı¨ve animals led to
the generation of abnormally large asymmetric pre-synaptic
terminals in CA1 stratum radiatum, with a greater number of
normal appearing vesicles. Prolonged silencing of activity caused
only minimal synaptic pathology at four weeks after BoNT/A
injection but not at longer time points. When BoNT/A was
infused into the prion-diseased mouse hippocampus, rates of
synaptic degeneration remained unaltered. Thus, contrary to our
expectations, silencing synapse activity neither prevented nor
indeed enhanced the degree of asymmetric synapse degeneration
in prion disease. We discuss in turn the action of BoNT/A on
naı¨ve central synapses and the lack of BoNT/A effects in prion
disease.
BoNT/A in the normal CNS
There are no electron microscopy studies on the long-term
consequences of delivering BoNT/A directly to the CNS. Previous
electron microscopy studies on the effect of BoNT/A and tetanus
neurotoxin on peripheral nerve terminals show the accumulation
of synaptic vesicles at the presynaptic site [28,29]. In this study we
have shown that 1 nM BoNT/A, a dose previously shown to
abolish excitatory neurotransmission and cell firing in the
hippocampus [17,35], leads to widespread cleavage of SNAP-25
that persists for at least 8 weeks the latest time point examined. We
Figure 5. BoNT/A has no significant impact on synaptic degeneration. (A) Percentages of healthy (open circles) and degenerating synapses
(filled circles) in the CA1 stratum radiatum during prion disease progression. Degenerating terminals increase while normal boutons decrease in
frequency from 10 to 16–18 weeks after delivery of the ME7 agent (one way ANOVA followed by Holm-Sidak test, p,0.05). Numbers of terminals
analyzed are as follows: 10 weeks, n = 263; 12 weeks, n = 371; 16 weeks, n = 367; 18 weeks, n = 398. (B) Percentages of healthy (open bars) and
degenerating synapses (filled bars) in prion+vehicle (prion+Veh) and prion+BoNT/A mice at 12 weeks into the disease. Percentages are identical in
the two groups (t-test, p = 0.97). (C) Density of normal synapses (open bars) and degenerating boutons (filled bars) in prion+vehicle (prion+Veh) and
prion+BoNT/A mice at 12 weeks into the disease. There are no statistically significant differences between the two groups (t-test, p.0.19). Number of
terminals analyzed are as follows: prion+vehicle, n = 327; prion+BoNT/A, n = 723.
doi:10.1371/journal.pone.0041182.g005
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detected ultrastructural changes in asymmetric terminals in the
stratum radiatum, the vast majority of which arise from axons of
CA3 pyramidal neurons. Following BoNT/A treatment, CA1
terminals were not only enlarged but had a larger complement of
synaptic vesicles. These synaptic vesicles had a normal shape and
size, and are suggestive of a continuing supply of mature vesicles
arriving at synapses and unable to fuse with the plasma membrane
to release their neurotransmitter. There was no evidence of
immature pleiomorphic vesicles [30] at the pre-synaptic terminal.
Presynaptic terminal areas were maximally increased 4 weeks after
BoNT/A, with a significant relaxation at 8 weeks. The return of
the presynaptic boutons towards their normal size at 8 weeks may
reflect an adaptation of the neuron to the lack of activity, as there
was clear evidence of persistence of high levels of cleaved SNAP-
25 in the hippocampus at 8 weeks (present results and [17]). Of
interest is that while the pre-synaptic terminals were enlarged, the
PSDs did not show a compensatory change in the absence of
neurotransmitter release. It is not the case that PSDs can not
enlarge since this is seen during progression of prion disease and
interpreted as a reactive response to the loss of synapses in the
stratum radiatum [36].
The increase in the density of synaptic vesicles in BoNT/A-
treated terminals is consistent with previous ultrastructural work
on peripheral neurons incubated with clostridial toxins [28,29,34].
Recently, Wree and collaborators reported axonal swellings and
varicosities following injection of BoNT/A into the rat striatum.
These swellings might correspond to enlarged synaptic terminals
as they contained the biosynthetic enzymes for acetylcholine and
dopamine [37].
In addition to enlargement of terminals, BoNT/A caused the
appearance of a small percentage of dark, degenerating synapses
4 weeks after injection. Since these dark profiles were not detected
at other times (2 and 8 weeks), we interpret this finding as
a transient wave of degeneration triggered by the activity blockade
in a subset of sensitive terminals. It is interesting to note that dark
synapses have been seen in association with hypoglossal neurons
following injection of BoNT/A into the tongue [38]. Recent
evidence showing that BoNT/A may be transferred transneur-
onally [17,27] suggests that the toxin may access the presynaptic
neuron and cause degeneration in some synapses innervating the
hypoglossal motor neurons.
In the long-term (8 weeks), BoNT/A caused no synaptic
degeneration and, consistently, there was the absence of a signif-
icant microglia response as shown by normal microglial cell
densities. It is interesting that the microglia do not respond to the
widespread silencing of synaptic activity in the CNS since recent
studies have suggested that microglia monitor synaptic health and
activity [39,40]. However, we cannot exclude that more subtle
changes in microglia morphology and/or function (not detectable
with Iba-1 labeling) occur as a result of synaptic silencing.
Activity and synaptic degeneration
The degeneration of asymmetric terminals is a conspicuous
feature of the early pathology in the ME7 model of prion disease
and precedes any detectable degeneration of cell bodies of CA3 or
CA1 pyramidal neurons [7,8]. The precise mechanisms leading to
synapse degeneration are poorly understood but as discussed
elsewhere [8] do not appear to be simply related to the
accumulation of protease resistant prion protein (PrPSc). There is
growing body or evidence to show in prion disease that the
accumulation of PrPSc is neither necessary or sufficient to lead to
neuronal degeneration [41,42], but by analogy with studies in
Alzheimer’s disease soluble oligomeric species of misfolded protein
may be critical [43,44]. How the misfolded protein targets the pre-
synaptic terminal leading to degeneration is unclear but early
changes in the synaptic vesicle proteins [8] suggest that uptake of
the misfolded peptide during the exocytosis-endocytosis cycle may
be involved. In keeping with this idea, elevated neural activity has
been shown to enhance synapse vulnerability in a mouse model of
Figure 6. Ultrastructural hallmarks of prion disease are not
impacted by BoNT/A treatment. Electron micrographs of CA1
stratum radiatum of the hippocampus illustrating control, vehicle-
exposed synapses (A, VEH) and neuropathological changes in
prion+vehicle (prion + VEH; B) and prion+BoNT/A animals (C) at
12 weeks following delivery of the ME7 agent. High magnification
pictures are shown in the insets. Note degenerating boutons with
curved PSDs in both prion+vehicle and prion+BoNT/A samples. Scale
bar = 500 nm (250 nm for insets).
doi:10.1371/journal.pone.0041182.g006
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synaptic degeneration [10]. In Alzheimer’s patients, brain areas
that develop the most Aß plaques also have the highest resting
activity [45]. We thus hypothesized that blockade of synaptic
activity may arrest or delay synapse loss during chronic
neurodegeneration.
To test this idea, we employed the ME7 mouse model of prion
disease that has been previously characterized in detail [46]. The
advantage of this model is that the neuropathology can be spatially
and temporally controlled by intracerebral delivery of the prion
agent. Injection of the ME7 agent into the hippocampus triggers
a transient inflammatory response that resolves by 4 weeks [33],
and synapse loss with associated behavioural impairments is
detected in the stratum radiatum by 12 weeks [47]. Synaptic
degeneration increases between 10 and 12 weeks after ME7
injection and reaches a plateau at 16–18 weeks (see Figure 5). We
thus chose to infuse BoNT/A in the prion-injected hippocampus
at 4 weeks, many weeks prior to first significant loss of synapses but
after the first inflammatory phase, and assessed numbers of
healthy/degenerating synapses in the CA1 stratum radiatum at
12 weeks into the disease. Thus, synaptic exocytosis was blocked
early in disease evolution and the evidence indicates, from staining
for cleaved SNAP-25, that even eight weeks after injection the
toxin is still active and blocking vesicle-mediated release of
neurotransmitter.
We found no evidence that BoNT/A protected synapses in the
stratum radiatum from neurodegeneration, indeed the ratio of
degenerating to intact synapses was the same in BoNT/A- and
vehicle-treated animals (Fig. 5B). Absolute numbers of normal/
dark terminals were also perfectly comparable between groups
(Fig. 5C), ruling out an acceleration/slowing down of the
degeneration process over the weeks preceding the analysis. A
model in which the misfolded protein requires neural activity to
kill presynaptic terminals is clearly not tenable. In the case of Aß
oligomers, it has been hypothesized that their direct binding to
plasma membranes of neurons could perturb the fine structure of
the phospholipid bilayer [44], thus resulting in signaling changes
and toxic effects proceeding via pathways largely independent of
electrical activity. The lack of impact of BoNT/A on synaptic
degeneration also suggests that toxic species of normal prion
protein (PrPc) or PrPSc must initiate neurodegeneration via
a receptor interaction that is not activity dependent. Similarly,
our data provide little support for a sequential model, in which the
disease-associated neurotoxic agent (i.e. the prion agent) first
causes synaptic dysfunction and then progresses through to
degeneration of the same terminals.
PrPSc may access the presynaptic element by pathways that are
not dependent on vesicle exo/endocytosis. It has been shown in
vitro that PrPc is rapidly internalized from the cell surface and re-
cycled back again in association with LRP1 [48] and the
conversion of PrPc to potentially toxic PrPSc may take place at
the plasma membrane before being internalized by clathrin
independent endocytosis [49]. If PrPc also mediates the impair-
ment of synaptic plasticity of Aß oligomers [50,51], a similar
mechanism of synaptic loss may operate in AD, although there is
little evidence of degenerating synapses in experimental studies on
the action of Aß peptides. It is of interest that the major effects of
Aß studied to date interfere with synaptic efficacy at the post-
synaptic site and inhibit long-term potentiation or enhance long-
term depression [52]. Our data suggest that toxicity leading to
degeneration involves different processes or perhaps different
peptide from those interfering with transmission. The identifica-
tion of these different species and the mechanisms of synaptic
degeneration remains a significant challenge in protein misfolding
diseases.
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